## Tarek K Rajji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6378880/publications.pdf

Version: 2024-02-01

229 papers 7,327 citations

50276 46 h-index 74 g-index

233 all docs

233 docs citations

times ranked

233

9775 citing authors

#	Article	IF	Citations
1	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. Alzheimer's and Dementia, 2023, 19, 226-243.	0.8	15
2	Association of functional connectivity of the executive control network or default mode network with cognitive impairment in older adults with remitted major depressive disorder or mild cognitive impairment. Neuropsychopharmacology, 2023, 48, 468-477.	5.4	3
3	Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. American Journal of Geriatric Psychiatry, 2022, 30, 54-64.	1.2	12
4	Assessing and stabilizing atypical plasticity in autism spectrum disorder using rTMS: Results from a proof-of-principle study. Clinical Neurophysiology, 2022, 141, 109-118.	1.5	10
5	Assessing the Longitudinal Relationship between Theta-Gamma Coupling and Working Memory Performance in Older Adults. Cerebral Cortex, 2022, 32, 1653-1667.	2.9	4
6	Invited letter: Integrated palliative care in a geriatric mental health setting during the COVIDâ€19 pandemic. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	5
7	Impact of Integrated Care Pathways Within the Framework of Collaborative Care on Older Adults With Anxiety, Depression, or Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, 30, 834-847.	1.2	3
8	Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction. Schizophrenia Research, 2022, 239, 160-167.	2.0	5
9	Time setting errors in the Clock Drawing Test are associated with both semantic and executive deficits. Applied Neuropsychology Adult, 2022, , 1-10.	1.2	3
10	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. Schizophrenia Research, 2022, 241, 113-115.	2.0	1
11	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. GeroScience, 2022, 44, 1575-1598.	4.6	4
12	Determining whether Sex and Zygosity modulates the association between ApoE4 and Psychosis in Neurodegenerative Disease Cohorts using the ONDRI platform. American Journal of Geriatric Psychiatry, 2022, 30, S90-S91.	1.2	0
13	Prevalence of mental health outcomes and effects of sex and mood or cognitive comorbidity in older adults during the COVID-19 pandemic. American Journal of Geriatric Psychiatry, 2022, 30, S115-S116.	1.2	1
14	PAS-MCI: Design and Rationale for a Randomized Controlled Trial to Enhance Prefrontal Cortical Plasticity and Working Memory in Individuals with Amnestic Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, 30, S53.	1.2	0
15	Cognitive Remediation Therapy for Participants with Late Life Schizophrenia. American Journal of Geriatric Psychiatry, 2022, 30, S125.	1.2	O
16	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	3
17	Cross-frequency coupling in psychiatric disorders: A systematic review. Neuroscience and Biobehavioral Reviews, 2022, 138, 104690.	6.1	16
18	P97. Outcomes and Clinical Implications of Intranasal Insulin on Cognition and Brain Function in Humans: A Systematic Review and Meta-Analysis. Biological Psychiatry, 2022, 91, S126.	1.3	0

#	Article	IF	Citations
19	P157. Atypical Resting State Frontal EEG Alpha Asymmetry in Autistic Adults: Preliminary Results. Biological Psychiatry, 2022, 91, S150.	1.3	0
20	Cognitive control, interference inhibition, and ordering of information during working memory in younger and older healthy adults. GeroScience, 2022, 44, 2291-2303.	4.6	1
21	Magnetic Seizure Therapy for the Treatment of Suicidality in Bipolar Depression. Biological Psychiatry, 2021, 90, e51-e53.	1.3	4
22	The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span. Schizophrenia Bulletin, 2021, 47, 249-257.	4.3	14
23	A doubleâ€blind, randomized, placeboâ€controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disorders, 2021, 23, 66-75.	1.9	7
24	Effects of Repetitive Transcranial Magnetic Stimulation on Working Memory Performance and Brain Structure in People With Schizophrenia Spectrum Disorders: A Double-Blind, Randomized, Sham-Controlled Trial. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 449-458.	1.5	5
25	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. Journal of Psychopharmacology, 2021, 35, 31-39.	4.0	5
26	Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 195-203.	1.9	72
27	A pilot study of magnetic seizure therapy for treatmentâ€resistant obsessive–compulsive disorder. Depression and Anxiety, 2021, 38, 161-171.	4.1	3
28	Mild cognitive impairment and major depressive disorder are associated with molecular senescence abnormalities in older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12129.	3.7	13
29	Neurodegenerative Cognitive Disorders. , 2021, , 443-462.		1
30	Canadian Platform for Trials in Noninvasive Brain Stimulation (CanStim) Consensus Recommendations for Repetitive Transcranial Magnetic Stimulation in Upper Extremity Motor Stroke Rehabilitation Trials. Neurorehabilitation and Neural Repair, 2021, 35, 103-116.	2.9	5
31	Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. Scientific Reports, 2021, 11, 2004.	3.3	8
32	Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy. Journal of Psychiatry and Neuroscience, 2021, 46, E88-E96.	2.4	7
33	Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 1239-1252.	1.2	3
34	Comparing cardiovascular risk factors in older persons with mild cognitive impairment and lifetime history of major depressive disorder. International Psychogeriatrics, 2021, , 1-7.	1.0	2
35	Enhancing Cognition in Older Persons: A Pilot Clinical Trial of Mindfulness-Based Stress Reduction (MBSR) and transcranial Direct Current Stimulation (tDCS). American Journal of Geriatric Psychiatry, 2021, 29, S105-S106.	1.2	0
36	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. NPJ Schizophrenia, 2021, 7, 22.	3.6	35

#	Article	IF	CITATIONS
37	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64
38	Anticipatory Parietal Alpha Desynchronization and Working Memory Performance and Capacity. Biological Psychiatry, 2021, 89, S254.	1.3	0
39	Less Anxiety, Better Learning, More Studies. American Journal of Geriatric Psychiatry, 2021, , .	1.2	0
40	Altered interhemispheric signal propagation in schizophrenia and depression. Clinical Neurophysiology, 2021, 132, 1604-1611.	1.5	5
41	MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. Sleep Medicine, 2021, 83, 83-88.	1.6	11
42	Transcranial magnetic stimulation indices of cortical excitability enhance the prediction of response to pharmacotherapy in late-life depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, , .	1.5	1
43	Differentiating transcranial magnetic stimulation cortical and auditory responses via single pulse and paired pulse protocols: A TMS-EEG study. Clinical Neurophysiology, 2021, 132, 1850-1858.	1.5	17
44	Neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) in treatment resistant depression. Clinical Neurophysiology, 2021, 132, 2306-2316.	1.5	32
45	Potency and variation in non-invasive brain stimulation: Time to act. Clinical Neurophysiology, 2021, 132, 2251-2252.	1.5	0
46	Dorsolateral prefrontal cortex excitability abnormalities in Alzheimer's Dementia: Findings from transcranial magnetic stimulation and electroencephalography study. International Journal of Psychophysiology, 2021, 169, 55-62.	1.0	16
47	A calcium fluorescence assay for quantification of cholinergic receptor activity of clinical drugs in serum - comparison with radioactive methods. Journal of Pharmacological and Toxicological Methods, 2021, 112, 107118.	0.7	0
48	Associations of visual paired associative learning task with global cognition and its potential usefulness as a screening tool for Alzheimer's Dementia. International Psychogeriatrics, 2021, 33, 1135-1144.	1.0	4
49	Noninvasive brain stimulation for the treatment of neurocognitive disorders: right for prime time?. Current Opinion in Psychiatry, 2021, 34, 129-135.	6.3	3
50	Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial. Mindfulness, 2021, 12, 1-13.	2.8	17
51	Reliability of the Clozapine:N-Desmethylclozapine (CLZ:NDMC) Ratio. Schizophrenia Bulletin Open, 2021, 2, .	1.7	2
52	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab. Canadian Geriatrics Journal, 2021, 24, 373-378.	1.2	6
53	Exercise priming with transcranial direct current stimulation: a study protocol for a randomized, parallel-design, sham-controlled trial in mild cognitive impairment and Alzheimer's disease. BMC Geriatrics, 2021, 21, 677.	2.7	5
54	Pharmacological mechanisms of interhemispheric signal propagation: a TMS-EEG study. Neuropsychopharmacology, 2020, 45, 932-939.	5.4	22

#	Article	IF	CITATIONS
55	Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology, 2020, 45, 276-282.	5.4	50
56	Evidence for prefrontal cortex hypofunctioning in schizophrenia through somatosensory evoked potentials. Schizophrenia Research, 2020, 215, 197-203.	2.0	9
57	The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of Affective Disorders, 2020, 262, 149-154.	4.1	14
58	The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opinion on Drug Safety, 2020, 19, 43-57.	2.4	33
59	A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease. Journal of ECT, 2020, 36, 211-215.	0.6	15
60	Effectively Caring for Individuals With Behavioral and Psychological Symptoms of Dementia During the COVID-19 Pandemic. Frontiers in Psychiatry, 2020, 11, 573367.	2.6	51
61	Theta–gamma coupling and ordering information: a stable brain–behavior relationship across cognitive tasks and clinical conditions. Neuropsychopharmacology, 2020, 45, 2038-2047.	5.4	19
62	DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES. American Journal of Geriatric Psychiatry, 2020, 28, S79-S80.	1.2	2
63	Vagally Mediated Heart Rate Variability Is Associated With Executive Function Changes in Patients With Treatmentâ€Resistant Depression Following Magnetic Seizure Therapy. Neuromodulation, 2020, , .	0.8	2
64	Magnetic Seizure Therapy for Suicidality in Treatment-Resistant Depression. JAMA Network Open, 2020, 3, e207434.	5.9	13
65	Dorsolateral prefrontal cortex metabolites and their relationship with plasticity in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045879.	0.8	3
66	Frontal-executive and corticolimbic structural brain circuitry in older people with remitted depression, mild cognitive impairment, Alzheimer's dementia, and normal cognition. Neuropsychopharmacology, 2020, 45, 1567-1578.	5.4	14
67	Treatment of Suicidality in Bipolar Depression With Magnetic Seizure Therapy: Clinical Effects and Neurophysiological Correlates. Biological Psychiatry, 2020, 87, S458-S459.	1.3	0
68	EVALUATING THE COGNITIVE EFFECTS OF EXERCISE PRIMING AND TRANSCRANIAL DIRECT CURRENT STIMULATION IN MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER'S DISEASE: THE EXPRESS STUDY. American Journal of Geriatric Psychiatry, 2020, 28, S75-S76.	1.2	0
69	Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years. Journal of Alzheimer's Disease, 2020, 74, 747-757.	2.6	9
70	Effects of bilateral transcranial direct current stimulation on working memory and global cognition in older patients with remitted major depression: A pilot randomized clinical trial. International Journal of Geriatric Psychiatry, 2020, 35, 1233-1242.	2.7	7
71	Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. Journal of Alzheimer's Disease, 2020, 76, 733-751.	2.6	27
72	Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review. PLoS ONE, 2020, 15, e0223029.	2.5	28

#	Article	IF	Citations
73	Gender impact on transcranial magnetic stimulation-based cortical excitability and cognition relationship in healthy individuals. NeuroReport, 2020, 31, 287-292.	1.2	9
74	Functional Competence and Cognition in Individuals With Amnestic Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2020, 68, 1787-1795.	2.6	2
75	Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer's Disease and Related Dementias. American Journal of Geriatric Psychiatry, 2020, 28, 712-721.	1.2	374
76	Why Do Some Older Adults Treated With Antidepressants Progress to Dementia?. Journal of Clinical Psychiatry, 2020, 81, .	2.2	5
77	Transcranial Magnetic and Electrical Stimulation in Alzheimer's Disease and Mild Cognitive Impairment: A Review of Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 2019, 106, 776-780.	4.7	42
78	Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. Journal of Neuroimaging, 2019, 29, 721-729.	2.0	6
79	EXAMINING THE IMPACT OF CARDIOVASCULAR RISK FACTORS ON NEUROPSYCHIATRIC SYMPTOMS IN THE PACT-MD STUDY. American Journal of Geriatric Psychiatry, 2019, 27, S202-S203.	1.2	1
80	Escitalopram for agitation in Alzheimer's disease (Sâ€CitAD): Methods and design of an investigatorâ€initiated, randomized, controlled, multicenter clinical trial. Alzheimer's and Dementia, 2019, 15, 1427-1436.	0.8	28
81	Clinical utility and prospective of TMS–EEG. Clinical Neurophysiology, 2019, 130, 802-844.	1.5	276
82	An inverse relationship between cortical plasticity and cognitive inhibition in late-life depression. Neuropsychopharmacology, 2019, 44, 1659-1666.	5.4	9
83	Association between Sleep Disturbances and Medial Temporal Lobe Volume in Older Adults with Mild Cognitive Impairment Free of Lifetime History of Depression. Journal of Alzheimer's Disease, 2019, 69, 413-421.	2.6	11
84	Changes in Theta but not Alpha Modulation Are Associated with Impairment in Working Memory in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 68, 1085-1094.	2.6	16
85	Unilateral and bilateral repetitive transcranial magnetic stimulation for treatmentâ€resistant lateâ€life depression. International Journal of Geriatric Psychiatry, 2019, 34, 822-827.	2.7	35
86	Early Clinical Exposure to Geriatric Psychiatry and Medical Students' Interest in Caring for Older Adults: A Randomized Controlled Trial. American Journal of Geriatric Psychiatry, 2019, 27, 745-751.	1.2	5
87	Delusions in Alzheimer Disease are Associated With Decreased Default Mode Network Functional Connectivity. American Journal of Geriatric Psychiatry, 2019, 27, 1060-1068.	1.2	22
88	CARDIOVASCULAR BURDEN AND COGNITION IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER. American Journal of Geriatric Psychiatry, 2019, 27, S132-S133.	1.2	1
89	Cognitive Functioning in Older Adults with Schizophrenia. , 2019, , 69-78.		0
90	Examining the Link Between Cardiovascular Risk Factors and Neuropsychiatric Symptoms in Mild Cognitive Impairment and Major Depressive Disorder in Remission. Journal of Alzheimer's Disease, 2019, 67, 1305-1311.	2.6	9

#	Article	IF	CITATIONS
91	Impaired brain plasticity as a potential therapeutic target for treatment and prevention of dementia. Expert Opinion on Therapeutic Targets, 2019, 23, 21-28.	3.4	21
92	Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls. Neuropsychopharmacology, 2019, 44, 898-906.	5.4	107
93	Altered Transcranial Magnetic Stimulation–Electroencephalographic Markers of Inhibition and Excitation in the Dorsolateral Prefrontal Cortex in Major Depressive Disorder. Biological Psychiatry, 2019, 85, 477-486.	1.3	81
94	Gray Matter Changes Associated With the Development of Delusions in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2019, 27, 490-498.	1.2	21
95	Impaired neuroplasticity in the prefrontal cortex in depression indexed through paired associative stimulation. Depression and Anxiety, 2018, 35, 448-456.	4.1	43
96	Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. Journal of Psychopharmacology, 2018, 32, 509-523.	4.0	79
97	Neurophysiology and cognitive reserve: A promising path. Clinical Neurophysiology, 2018, 129, 286-287.	1.5	5
98	Decreased Default Mode Network Functional Connectivity in Alzheimer's Disease Patients with Delusions. American Journal of Geriatric Psychiatry, 2018, 26, S134.	1.2	1
99	Reduced Short-Latency Afferent Inhibition in Prefrontal but not Motor Cortex and Its Association With Executive Function in Schizophrenia: A Combined TMS-EEG Study. Schizophrenia Bulletin, 2018, 44, 193-202.	4.3	29
100	Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology, 2018, 43, 354-361.	5.4	13
101	Allostatic load but not medical burden predicts memory performance in lateâ€ife bipolar disorder. International Journal of Geriatric Psychiatry, 2018, 33, 546-552.	2.7	10
102	Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1885-1895.	4.3	29
103	Community based telepsychiatry service for older adults residing in a rural and remote regionutilization pattern and satisfaction among stakeholders. BMC Psychiatry, 2018, 18, 316.	2.6	38
104	Assessment of neuroplasticity in late-life depression with transcranial magnetic stimulation. Journal of Psychiatric Research, 2018, 105, 63-70.	3.1	6
105	Late-Life Schizophrenia and Gender Matters. American Journal of Geriatric Psychiatry, 2018, 26, 1220-1221.	1.2	0
106	Reduced GABAergic cortical inhibition in aging and depression. Neuropsychopharmacology, 2018, 43, 2277-2284.	5.4	34
107	Characteristics of ictal EEG in Magnetic Seizure Therapy at various stimulation frequencies. Clinical Neurophysiology, 2018, 129, 1770-1779.	1.5	14
108	Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology, 2018, 43, 2231-2238.	5.4	104

#	Article	IF	CITATIONS
109	Theta-Gamma Coupling and Working Memory in Alzheimer's Dementia and Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 101.	3.4	103
110	Pharmacological Modulation of Long-Term Potentiation-Like Activity in the Dorsolateral Prefrontal Cortex. Frontiers in Human Neuroscience, 2018, 12, 155.	2.0	10
111	Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. BMC Psychiatry, 2018, 18, 227.	2.6	8
112	Statins and cognition in lateâ€life bipolar disorder. International Journal of Geriatric Psychiatry, 2018, 33, 1355-1360.	2.7	6
113	Ordering Information in Working Memory and Modulation of Gamma by Theta Oscillations in Humans. Cerebral Cortex, 2017, 27, bhv326.	2.9	44
114	Impaired theta-gamma coupling during working memory performance in schizophrenia. Schizophrenia Research, 2017, 189, 104-110.	2.0	67
115	Resting-state EEG gamma power and theta–gamma coupling enhancement following high-frequency left dorsolateral prefrontal rTMS in patients with depression. Clinical Neurophysiology, 2017, 128, 424-432.	1.5	111
116	Sharpening a classic scalpel to face the growth of Alzheimer's dementia. Clinical Neurophysiology, 2017, 128, 658-659.	1.5	0
117	Clinical Effectiveness and Tolerability of Electroconvulsive Therapy in Patients with Neuropsychiatric Symptoms of Dementia. Journal of Alzheimer's Disease, 2017, 57, 45-51.	2.6	22
118	Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia. Current Psychiatry Reports, 2017, 19, 36.	4.5	41
119	Creation of a Psychosocial Interventions Clinic for Elderly Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2017, 25, S99.	1.2	0
120	The Impact of Primary Care on Medical Health Outcomes for Elderly Patients with Psychotic Disordersâ€"a Comparison between Two Hospital Systems in Canada. American Journal of Geriatric Psychiatry, 2017, 25, S106-S107.	1.2	0
121	Abnormal self-schema in semantic memory in major depressive disorder: Evidence from event-related brain potentials. Biological Psychology, 2017, 126, 41-47.	2.2	26
122	Pharmacotherapy of major depression in late life: what is the role of new agents?. Expert Opinion on Pharmacotherapy, 2017, 18, 599-609.	1.8	21
123	Gray Matter Neuritic Microstructure Deficits in Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2017, 82, 726-736.	1.3	79
124	Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease. Neurodegenerative Disease Management, 2017, 7, 317-329.	2.2	30
125	Extent of Dorsolateral Prefrontal Cortex Plasticity and Its Association With Working Memory in Patients With Alzheimer Disease. JAMA Psychiatry, 2017, 74, 1266.	11.0	118
126	Collaborative Care for Psychiatric Disorders in Older Adults: A Systematic Review. Canadian Journal of Psychiatry, 2017, 62, 761-771.	1.9	32

#	Article	IF	CITATIONS
127	677. Evidence for Prefrontal Cortex Hypoexcitability in Schizophrenia through Somatosensory Evoked Potentials. Biological Psychiatry, 2017, 81, S274.	1.3	O
128	311. DLPFC Neuroplasticity and Working Memory Performance in Alzheimer's Disease. Biological Psychiatry, 2017, 81, S128.	1.3	1
129	702. The Behavioural and Neural Correlates of Social Cognition in Youth with Mental Illness. Biological Psychiatry, 2017, 81, S284-S285.	1.3	0
130	Impairment of Neuroplasticity in the Dorsolateral Prefrontal Cortex by Alcohol. Scientific Reports, 2017, 7, 5276.	3.3	19
131	Are We Ready for Mental Health Aging?. Canadian Journal of Psychiatry, 2017, 62, 752-753.	1.9	0
132	70. Cortical Inhibition as a High Potential Biomarker of Response across Brain Stimulation Modalities in Treatment Resistant Depression. Biological Psychiatry, 2017, 81, S29.	1.3	0
133	Characterization of Glutamatergic and GABAA-Mediated Neurotransmission in Motor and Dorsolateral Prefrontal Cortex Using Paired-Pulse TMS–EEG. Neuropsychopharmacology, 2017, 42, 502-511.	5 <b>.</b> 4	124
134	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2017, 25, 1-10.	1.2	18
135	Simulation in Undergraduate Psychiatry: Exploring the Depth of Learner Engagement. Academic Psychiatry, 2017, 41, 251-261.	0.9	43
136	Differential effects of cannabis dependence on cortical inhibition in patients with schizophrenia and non-psychiatric controls. Brain Stimulation, 2017, 10, 275-282.	1.6	8
137	Paired-Associative Stimulation-Induced Long-term Potentiation-Like Motor Cortex Plasticity in Healthy Adolescents. Frontiers in Psychiatry, 2017, 8, 95.	2.6	9
138	Reduced Prefrontal Short—Latency Afferent Inhibition in Older Adults and Its Relation to Executive Function: A TMS-EEG Study. Frontiers in Aging Neuroscience, 2017, 9, 119.	3.4	14
139	Characterization of the influence of age on GABAA and glutamatergic mediated functions in the dorsolateral prefrontal cortex using paired-pulse TMS-EEG. Aging, 2017, 9, 556-572.	3.1	47
140	Magnetic Seizure Therapy in Treatment-Resistant Schizophrenia: A Pilot Study. Frontiers in Psychiatry, 2017, 8, 310.	2.6	15
141	Anticholinergic Burden and Cognition in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2017, 78, e1284-e1290.	2.2	30
142	Schizophrenia and Cognition in Late Life. Mental Health and Illness Worldwide, 2017, , 263-275.	0.1	0
143	A Review of Impaired Neuroplasticity in Schizophrenia Investigated with Non-invasive Brain Stimulation. Frontiers in Psychiatry, 2016, 7, 45.	2.6	22
144	Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study. Journal of Psychiatry and Neuroscience, 2016, 41, E58-E66.	2.4	76

#	Article	IF	CITATIONS
145	A combined TMS-EEG study of short-latency afferent inhibition in the motor and dorsolateral prefrontal cortex. Journal of Neurophysiology, 2016, 116, 938-948.	1.8	31
146	Neuroplasticity Deficits and Working Memory Performance in Individuals with Early Alzheimer's Disease. American Journal of Geriatric Psychiatry, 2016, 24, S112.	1.2	0
147	The Efficacy of Unilateral and Bilateral Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression. American Journal of Geriatric Psychiatry, 2016, 24, S69-S71.	1.2	1
148	Decreased Brain-Derived Neurotrophic Factor in Older Adults with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2016, 24, 596-601.	1.2	23
149	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology, 2016, 233, 3803-3813.	3.1	11
150	Effects of varenicline on motor cortical plasticity in non-smokers with schizophrenia. Schizophrenia Research, 2016, 178, 50-55.	2.0	2
151	An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia. International Journal of Geriatric Psychiatry, 2016, 31, 1116-1123.	2.7	11
152	A meta-analysis of the effects of aging on motor cortex neurophysiology assessed by transcranial magnetic stimulation. Clinical Neurophysiology, 2016, 127, 2834-2845.	1.5	117
153	Late Life Schizophrenia: Advances in Research. American Journal of Geriatric Psychiatry, 2016, 24, S5.	1.2	1
154	Indicators for Remission of Suicidal Ideation Following Magnetic Seizure Therapy in Patients With Treatment-Resistant Depression. JAMA Psychiatry, 2016, 73, 337.	11.0	102
155	The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. Schizophrenia Research, 2016, 170, 330-335.	2.0	19
156	Integrated Care Pathways for Schizophrenia: A Scoping Review. Administration and Policy in Mental Health and Mental Health Services Research, 2016, 43, 760-767.	2.1	13
157	Brain Stimulation in Alcohol Use Disorders: Investigational and Therapeutic Tools. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 5-13.	1.5	10
158	Alcohol Intoxication by Binge Drinking Impairs Neuroplasticity. Brain Stimulation, 2016, 9, 27-32.	1.6	16
159	Deficits in GABAA receptor function and working memory in non-smokers with schizophrenia. Schizophrenia Research, 2016, 171, 125-130.	2.0	14
160	Systematic Review of Cognitive Effects of Electroconvulsive Therapy in Late-Life Depression. American Journal of Geriatric Psychiatry, 2016, 24, 547-565.	1.2	52
161	Threshold of Dopamine D <sub>2/3</sub> Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, e1557-e1563.	2.2	11
162	Schizophrenia and Cognition in Late Life. Mental Health and Illness Worldwide, 2016, , 1-13.	0.1	0

#	Article	IF	CITATIONS
163	Magnetic Seizure Therapy-induced Mania. Journal of ECT, 2015, 31, e4-e6.	0.6	7
164	NEUROBIOLOGICAL PREDICTORS OF RESPONSE TO DORSOLATERAL PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN DEPRESSION: A SYSTEMATIC REVIEW. Depression and Anxiety, 2015, 32, 871-891.	4.1	63
165	Cognitive remediation for older communityâ€dwelling individuals with schizophrenia: a pilot and feasibility study. International Journal of Geriatric Psychiatry, 2015, 30, 1129-1134.	2.7	10
166	Predicting hospital length of stay for geriatric and adult patients with schizophrenia. Journal of Hospital Administration, 2015, 4, 15.	0.1	6
167	Assessing and Stabilizing Aberrant Neuroplasticity in Autism Spectrum Disorder: The Potential Role of Transcranial Magnetic Stimulation. Frontiers in Psychiatry, 2015, 6, 124.	2.6	18
168	Functional Consequences of Neurite Orientation Dispersion and Density in Humans across the Adult Lifespan. Journal of Neuroscience, 2015, 35, 1753-1762.	3.6	120
169	Response to Thornton et al American Journal of Psychiatry, 2015, 172, 1259-1260.	7.2	3
170	Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up. Schizophrenia Research, 2015, 169, 69-75.	2.0	10
171	Superficial white matter as a novel substrate of age-related cognitive decline. Neurobiology of Aging, 2015, 36, 2094-2106.	3.1	65
172	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. JAMA Psychiatry, 2015, 72, 927.	11.0	77
173	Deep Brain Stimulation Modulates Gamma Oscillations and Theta–Gamma Coupling in Treatment Resistant Depression. Brain Stimulation, 2015, 8, 1033-1042.	1.6	47
174	Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to <i>N</i> -Desmethylclozapine. American Journal of Psychiatry, 2015, 172, 579-585.	7.2	63
175	Hippocampal (subfield) volume and shape in relation to cognitive performance across the adult lifespan. Human Brain Mapping, 2015, 36, 3020-3037.	3.6	101
176	Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. Schizophrenia Research, 2015, 165, 157-162.	2.0	40
177	Oxidative Stress in Older Patients with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2015, 23, 314-319.	1.2	34
178	Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. Schizophrenia Bulletin, 2015, 41, 44-56.	4.3	69
179	The Impact of Aging, Cognition, and Symptoms on Functional Competence in Individuals With Schizophrenia Across the Lifespan. Schizophrenia Bulletin, 2015, 41, 374-381.	4.3	55
180	Disrupted Prefrontal Interhemispheric Structural Coupling in Schizophrenia Related to Working Memory Performance. Schizophrenia Bulletin, 2014, 40, 914-924.	4.3	28

#	Article	IF	CITATIONS
181	The effects of aging on insight into illness in schizophrenia: a review. International Journal of Geriatric Psychiatry, 2014, 29, 1145-1161.	2.7	58
182	The VAGUS insight into psychosis scale – Self-report and clinician-rated versions. Psychiatry Research, 2014, 220, 1084-1089.	3.3	41
183	The VAGUS- Self-Report & Clinician-Rated Versions: A Novel Insight into Psychosis Scale for Use Across the Adult Late-Life Span. American Journal of Geriatric Psychiatry, 2014, 22, S93-S94.	1.2	0
184	Brain Stimulation in the Treatment of Late-Life Severe Mental Illness Other than Unipolar Nonpsychotic Depression. American Journal of Geriatric Psychiatry, 2014, 22, 216-240.	1.2	25
185	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. American Journal of Geriatric Psychiatry, 2014, 22, 1007-1016.	1.2	24
186	Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 83-91.	4.8	15
187	Decrease Brain-Derived Neurotrophic Factor (BDNF) in Older Patients with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2014, 22, S109.	1.2	1
188	Cognitive Remediation for Older Patients with Schizophrenia: A Pilot Study. American Journal of Geriatric Psychiatry, 2014, 22, S91-S92.	1.2	0
189	Age-related differences in working memory evoked gamma oscillations. Brain Research, 2014, 1576, 43-51.	2.2	18
190	Cognition, Function, and Disability in Patients with Schizophrenia: A Review of Longitudinal Studies. Canadian Journal of Psychiatry, 2014, 59, 13-17.	1.9	111
191	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. Schizophrenia Bulletin, 2013, 39, 564-574.	4.3	109
192	Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia. Human Brain Mapping, 2013, 34, 1035-1043.	3.6	38
193	Can Repetitive Magnetic Stimulation Improve Cognition in Schizophrenia? Pilot Data from a Randomized Controlled Trial. Biological Psychiatry, 2013, 73, 510-517.	1.3	116
194	Alterations of Superficial White Matter in Schizophrenia and Relationship to Cognitive Performance. Neuropsychopharmacology, 2013, 38, 1954-1962.	5.4	113
195	Lack of Insight in Late-Life Schizophrenia: A Function of Illness Severity and Premorbid Intellectual Functioning. American Journal of Geriatric Psychiatry, 2013, 21, S120-S121.	1.2	0
196	Advances in Late Life Schizophrenia Research. American Journal of Geriatric Psychiatry, 2013, 21, S5-S6.	1.2	0
197	Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: AÂStudy Using the MATRICS Consensus Cognitive Battery. American Journal of Geriatric Psychiatry, 2013, 21, 108-118.	1.2	68
198	A Comparison of the E-BEHAVE-AD, NBRS, and NPI in Quantifying Clinical Improvement in the Treatment of Agitation and Psychosis Associated With Dementia. American Journal of Geriatric Psychiatry, 2013, 21, 78-87.	1.2	30

#	Article	IF	Citations
199	Insight into illness in late-life schizophrenia: A function of illness severity and premorbid intellectual function. Schizophrenia Research, 2013, 150, 217-222.	2.0	10
200	Cognitive and Functional Ability in Older Adults with Schizophrenia. American Journal of Geriatric Psychiatry, 2013, 21, S119.	1.2	0
201	Neuroimaging Evidence for the Deficit Subtype of Schizophrenia. JAMA Psychiatry, 2013, 70, 472.	11.0	137
202	Modulating neural plasticity with non-invasive brain stimulation in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 621-631.	3.2	24
203	PAS-Induced Potentiation of Cortical-Evoked Activity in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology, 2013, 38, 2545-2552.	5.4	82
204	Neuroplasticity-Based Brain Stimulation Interventions in the Study and Treatment of Schizophrenia: A Review. Canadian Journal of Psychiatry, 2013, 58, 93-98.	1.9	26
205	Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia. American Journal of Geriatric Psychiatry, 2012, 20, 53-60.	1.2	44
206	A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World Journal of Biological Psychiatry, 2012, 13, 423-435.	2.6	88
207	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 2012, 197, 1-6.	3.3	148
208	Age-related decline in white matter tract integrity and cognitive performance: A DTI tractography and structural equation modeling study. Neurobiology of Aging, 2012, 33, 21-34.	3.1	274
209	Cholinergic pathways and cognition in patients with schizophrenia: A pilot study. Schizophrenia Research, 2012, 139, 46-52.	2.0	8
210	Myelin-Associated Glycoprotein Gene and Brain Morphometry in Schizophrenia. Frontiers in Psychiatry, 2012, 3, 40.	2.6	32
211	Management of Schizophrenia in Late Life with Antipsychotic Medications. Drugs and Aging, 2011, 28, 961-980.	2.7	26
212	Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophrenia Research, 2011, 133, 54-62.	2.0	99
213	The ZNF804A Gene: Characterization of a Novel Neural Risk Mechanism for the Major Psychoses. Neuropsychopharmacology, 2011, 36, 1871-1878.	5.4	58
214	Exploring the effect of inducing long-term potentiation in the human motor cortex on motor learning. Brain Stimulation, 2011, 4, 137-144.	1.6	33
215	Use of Lithium in the Treatment of Bipolar Disorder in Late-Life. Current Psychiatry Reports, 2011, 13, 488-492.	4.5	27
216	Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders. PLoS ONE, 2011, 6, e20982.	2.5	58

#	Article	IF	CITATIONS
217	Clozapine and Global Cognition in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 431-436.	1.4	35
218	Sensitivity to Antipsychotic Drugs in Older Adults. Current Psychiatry Reports, 2010, 12, 28-33.	4.5	35
219	Differentiating the Cognitive Profile of Schizophrenia from That of Alzheimer Disease and Depression in Late Life. PLoS ONE, 2010, 5, e10151.	2.5	29
220	Diffusion tensor tractography findings in schizophrenia across the adult lifespan. Brain, 2010, 133, 1494-1504.	7.6	131
221	The MMSE is not an adequate screening cognitive instrument in studies of late-life depression. Journal of Psychiatric Research, 2009, 43, 464-470.	3.1	37
222	Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study. Therapeutic Drug Monitoring, 2009, 31, 360-366.	2.0	57
223	D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 571-575.	1.4	41
224	Use of Antidepressants in Late-Life Depression. Drugs and Aging, 2008, 25, 841-853.	2.7	38
225	Nature and course of cognitive function in late-life schizophrenia: A systematic review. Schizophrenia Research, 2008, 102, 122-140.	2.0	110
226	Gray Matter Changes in Late Life Depression—a Structural MRI Analysis. Neuropsychopharmacology, 2008, 33, 2566-2572.	5 <b>.</b> 4	125
227	The Role of CA3 Hippocampal NMDA Receptors in Paired Associate Learning. Journal of Neuroscience, 2006, 26, 908-915.	3.6	91
228	Individualized realâ€time prediction of working memory performance by classifying electroencephalography signals. International Journal of Imaging Systems and Technology, 0, , .	4.1	2
229	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Denomic Medicine, 0, , .	1.2	3